The availability of sufficient protein of good quality can be rate limiting for many drug discovery programs, as a lack of target protein supply can hamper the ability to establish hit screening assays and to complete structural studies.
Domainex's biology team is able to clone and express drug targets of interest and can produce protein at the required levels by screening all possible protein constructs; for ongoing biochemical compound screening or structural studies, extremely quickly!
Domainex's Proprietary Technology - Combinatorial Domain Hunting (CDH)
In situations where standard molecular biology approaches will not be suitable or time is crucial, Domainex's proprietary Combinatorial Domain Hunting (CDH) approach will enable the fast identification of suitable protein constructs.
CDH is the unique, proprietary technology for quickly identifying soluble, highly expressible constructs of drug target proteins, that are able to bind ligand and are suitable for use in structural studies. This results in the ability to develop drug target binding or activity assays and to complete compound screening within exceptionally fast timelines.
CDH combines a method for the production of unbiased finely-sampled gene-fragment libraries, with a screening protocol that provides 'holistic' readout of solubility, ligand binding and yield for thousands of protein fragments.
CDH has an established pedigree: over 50 genes have been studied to date, including projects for many of the 'Top 20' global pharmaceutical companies (click her to view UCB press release on successful use of CDH technology). The entire process takes only 3-4 months from target to binding assay and can enable significant advancement in early discovery phase programs.
Following the identification of positive clones that express significant amounts of soluble drug target protein, protein can also be purified for use in x-ray crystallography studies.
For more information regarding Domainex’s CDH drug discovery technology platform, please contact us at email@example.com.